INFLAMACION Y ENFERMEDAD CARDIOVASCULAR.

Slides:

Advertisements

Similar presentations

Comment Vol 377 February 12, 2011 Stemming the global tsunami of cardiovascular disease.

Advertisements

Robert M. Guthrie, MD Professor of Emergency Medicine

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

HDL CHOLESTEROL REVISITED-- A RELIABLE DIAGNOSTIC TOOL OR JUST A PASSING FANCY? GARY A. LOPEZ, M.D.

Factors That Increase the Risk of Myopathy in People Taking Statins Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114: ) Jones PH, Davidson.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

 High density lipoproteins (HDL) protect against cardiovascular disease  A novel mechanism for raising HDL levels is to inhibit a protein known as CETP.

William B. Kannel, MD, FACC Former Director, Framingham Heart Study

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

Philip J. Barter, et al. Circulation 2011;124:

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟８階カンファレンス室.

Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael.

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer.

ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.

Low HDL remains a predictor of cardiovascular risk in statin-treated patients Barter P et al., N Engl J Med 2007; 357:

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:

Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes Featured Article:

Azithromycin for the Secondary Prevention of Coronary Events J. Thomas Grayston, M.D., Richard A. Kronmal, Ph.D., Lisa A. Jackson, M.D., Alfred F. Parisi,

Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.

CETP inhibition: Where are we now? Prof. John Kastelein Academic Medical Centre Amsterdam, The Netherlands.

Yale Mitchel, MD Cardiovascular Disease Department

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on.

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

The SPRINT Research Group

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.

European Society of Cardiology 2017 Clinical Trial Update I

Update on Anacetrapib, a Novel CETP Inhibitor

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Update on the CETP inhibitor Anacetrapib

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where are We Today? H. Bryan Brewer, Jr. Washington Cardiovascular Associates Washington.

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

AIM HIGH Niacin plus Statin to prevent vascular events

Senior Medical Director, Cardiovascular

ILLUMINATE - Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events.

First time a CETP inhibitor shows reduction of serious CV events

Oxford Niacin Trial.

What is the likely mechanism by which HDL-C reduces coronary heart disease?

FATS- Familial Atherosclerosis Treatment Study

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

Neil J. Stone et al. JACC 2014;63:

Diabetes and Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Updates in Cardiovascular Medicine

Description of studies for pooled analyses

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Contemporary Evidence-Based Guidelines

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Potential Mechanisms of Adverse Outcomes Associated with Torcetrapib

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

INFLAMACION Y ENFERMEDAD CARDIOVASCULAR

MICROBIOMA HUMANO Y ENFERMEDAD CARDIOVASCULAR

LDL Y ENFERMEDAD CARDIOVASCULAR: MÁS ALLÁ DE LAS ESTATINAS

HDL Y ENFERMEDAD CARDIOVASCULAR

HDL and Cardiovascular-Disease Risk — Time for a New Approach? N Engl J Med 2011; 364: January 13, 2011 Editorial Jay Heinecke, M.D.

Clinical Implications of Basic Research Sorting Out Cholesterol and Coronary Artery Disease Patrick Linsel-Nitschke, M.D., Nilesh J. Samani, M.D., M.B., Ch.B., and Heribert Schunkert, M.D. N Engl J Med 2010; 363:

Sortilin 1 and the Risk of Coronary Disease. Linsel-Nitschke P et al. N Engl J Med 2010;363:

Original Article Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease Christopher P. Cannon, M.D., Sukrut Shah, Ph.D., R.Ph., Hayes M. Dansky, M.D., Michael Davidson, M.D., Eliot A. Brinton, M.D., Antonio M. Gotto, Jr., M.D., D.Phil., Michael Stepanavage, M.S., Sherry Xueyu Liu, M.S., Patrice Gibbons, M.S., Tanya B. Ashraf, B.A., Jennifer Zafarino, M.S., Yale Mitchel, M.D., Philip Barter, M.D., Ph.D., for the DEFINE Investigators N Engl J Med Volume 363(25): December 16, 2010

Study Overview In this trial, anacetrapib, a cholesteryl ester transfer protein inhibitor, was shown to reduce LDL cholesterol by 40% in patients receiving maximal statin therapy and to increase HDL cholesterol by 138%, as compared with placebo.

Changes in Cholesterol Levels and Blood Pressure during the Study Period. Cannon CP et al. N Engl J Med 2010;363:

Conclusions Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib.

EPIGENÉTICA Y ENFERMEDAD CARDIOVASCULAR

INSULINORESISTENCIA Y ENFERMEDAD CARDIOVASCULAR

Effects of Thiazolidinediones. Kahn BB, McGraw TE. N Engl J Med 2010;363:

A Comparison of PPARγ Activity in Lean and Obese Persons. Kahn BB, McGraw TE. N Engl J Med 2010;363:

NUTRICIÓN Y ENFERMEDAD CARDIOVASCULAR

REPROGRAMACIÓN CELULAR Y ENFERMEDAD CARDIOVASCULAR

Clinical Implications of Basic Research Reprogramming Fibroblasts into Cardiomyocytes Charles E. Murry, M.D., Ph.D., and William T. Pu, M.D. N Engl J Med 2011; 364:177-17

The Path from Fibroblast to Cardiomyocyte. Murry CE, Pu WT. N Engl J Med 2011;364:

LA POBREZA Y ENFERMEDAD CARDIOVASCULAR